ClinicalTrials.gg
RecruitingNCT05190471Updated Mar 10, 2025

A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

A Phase 1 interventional study of BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide and Decitabine (in combination with BP1002) in Acute Myeloid Leukemia, in Relapse and Acute Myeloid Leukemia Refractory, sponsored by Bio-Path Holdings, Inc.. Recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-10.

Sponsored by Bio-Path Holdings, Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2022; still recruiting 4 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 121 studies testing decitabine in Leukemia, Myeloid, Acute — 20 open to participants now, 33 under way, 2 of them phase 3. Decitabine · Leukemia, Myeloid, Acute.

Planned enrollment
45th of 120
48 · median 32
Started
2022
with 6 others
Phase 1
37 of 121
6 open now
Primary completion
2027-03
later than 14 of 32 live
Registered
97th of 121
by date

Among the 121 studies testing decitabine in Leukemia, Myeloid, Acute, this one is the 45th largest by planned enrollment of the 120 interventional ones that give a count, is one of 7 that started in 2022, is one of 37 in phase 1, reaches primary completion later than 14 of the 32 other live ones, and was the 97th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

20 of the 121 studies testing decitabine in Leukemia, Myeloid, Acute are open now, in 5 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About decitabine

Decitabine: first FDA approval 2006 (DACOGEN), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 121 studies testing decitabine in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

This study evaluates the safety and tolerability of escalating doses of BP1002 (Liposomal Bcl-2 Antisense Oligodeoxynucleotide) in patients with refractory/relapsed AML. The study is designed to assess the safety profile, identify DLTs, biologically effective doses, PK, PD and potential anti-leukemic effects of BP1002 as single agent (dose escalation phase) followed by assessing BP1002 in combination with decitabine (dose expansion phase).

03

Conditions studied

  • Acute Myeloid Leukemia, in Relapse
  • Acute Myeloid Leukemia Refractory
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults ≥18 years of age, with histologic evidence of /relapsed AML who have failed treatment with available therapies known to be active for refractory/relapsed AML
  2. (ECOG) Performance Status Score of 0, 1 or 2
  3. For the dose expansion phase, participants with documented diagnosis of AML who are eligible for decitabine therapy
  4. Participants must have adequate hepatic and renal functions as defined by:

    1. (AST) and alanine transaminase (ALT) ≤2.5 times the (ULN); and
    2. Usually total ≤ 1.5 ULN. In specific cases the PI may request a waiver of this requirement with medical justification and agreement with the medical monitor and Bio-Path Holdings. And;
    3. Estimated of at least 60 mL/min. These estimations are calculated using the Cockcroft-Gault equation.
  5. Female participants of must agree to use an acceptable method of (i.e. a hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide or abstinence) for the duration of the study and for at least 6 months after the last dose of study drug or decitabine
  6. Male participants must agree to use an acceptable method of contraception for the duration of the study
  7. Recovered from the effects of any prior surgery, radiotherapy, or antineoplastic treatment (with the exception of alopecia), based on Investigator assessment
  8. Participants must be willing and able to provide written

Exclusion criteria

Exclusion Criteria:

  1. Active non-hematologic or lymphoid other than AML treated with immunotherapy, targeted therapy or chemotherapy within the previous 12 months
  2. Known, active leukemia requiring intrathecal therapy. NOTE: Participants with a history of CNS disease may be allowed to participate based on at least 1 documented, negative spinal fluid assessment within 28 days prior to Screening
  3. Isolated potentially treatable extramedullary leukemia without also meeting bone marrow criteria for acute leukemia (for AML usually ≥ 5% blasts in BMA or ). Participants may have leukemia with lower blast counts (Döhner 2017). Bio-Path Holdings and Investigator concurrence required.
  4. Acute promyelocytic leukemia (APL) with t(15;17)(q22;q12) PML-RARA
  5. Chronic myeloid leukemia in any phase
  6. Receipt of any anti-cancer therapy within 14 days prior to C1D1, with the exception of hydroxyurea or leukapheresis
  7. Participants may not be receiving any other agents
  8. Female participants who are pregnant or breast-feeding
  9. Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
  10. Participants with (HIV) infection who have \< 350 cells/mcL or with clinically active or C infection
  11. History of any to hypomethylating agents, unless reaction is deemed irrelevant to the study by the Investigator and Medical Monitor
  12. Unresolved toxicity higher than Grade 1 attributed to any prior therapy or procedure, excluding alopecia
  13. Presence of concurrent conditions that, in the opinion of the Investigator and/or Medical Monitor, may compromise the participant's ability to tolerate study treatment or interfere with any aspect of study conduct or interpretation of results. This includes, but is not limited to, unstable or uncontrolled angina, (NYHA) class III or IV congestive heart failure, uncontrolled and sustained hypertension, cardiac dysrhythmia or clinically significant baseline abnormality (e.g., >470 msec)
  14. Within the past 6 months, has had any of the following: myocardial infarction, unstable angina pectoris, coronary/peripheral artery bypass graft, cerebrovascular accident or
  15. Uncontrolled seizure disorder (i.e., seizures within the past 2 months)
  16. Unable or unwilling to communicate or cooperate with the Investigator or follow the protocol for any reason
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Relapsed/Refractory AML - BP1002 monotherapy

    BP1002 monotherapy dose escalation

    Drug: BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide

  • Experimental
    Relapsed/Refractory AML - BP1002 in combination with decitabine

    BP1002 single dose in combination with decitabine

    Drug: BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide · Drug: Decitabine (in combination with BP1002)

Interventions

  • DrugBP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide

    Drug page: OblimersenStudies of OblimersenOblimersen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Dose escalation of BP1002 monotherapy

    Also known as: Liposomal Bcl-2; L-Bcl-2

  • DrugDecitabine (in combination with BP1002)

    Drug page: DecitabineStudies of DecitabineDecitabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Dose expansion of BP1002 in combination with decitabine

    Also known as: Decitabine

06

What researchers measure

Primary outcomes

  1. Identify Dose Limiting Toxicity (DLT) of BP1002

    Identify DLT of BP1002 using non-hematologic and hematologic measures per NCI CTCAE criteria

    Time frame: 30 days

  2. Identify and grade treatment-emergent adverse events (TEAE) of escalating doses of BP1002

    Identify TEAE of BP1002 using non-hematologic and hematologic measures per NCI CTCAE criteria

    Time frame: 30 days

  3. Identify and grade treatment-emergent laboratory abnormalities of escalating doses of BP1002

    Identify and grade treatment-emergent laboratory abnormalities of escalating doses of BP1002 using non-hematologic and hematologic measure per NCI CTCAE criteria

    Time frame: 30 days

  4. Recommended Phase 2 (RP2D) of BP1002

    Determine RP2D by evaluating Maximally Tolerated Dose (MTD) data

    Time frame: 210 days

  5. Determine plasma pharmacokinetics (PK) of BP1002 using maximum plasma drug concentration

    Evaluate plasma PK of BP1002 using maximum plasma drug concentration (Cmax)

    Time frame: 30 days

  6. Determine plasma pharmacokinetics (PK) of BP1002 using volume of distribution

    Evaluate in vivo PK of BP1002 using volume of distribution (Vd)

    Time frame: 30 days

  7. Determine plasma pharmacokinetics (PK) of BP1002 using elimination rate constant

    Evaluate in vivo PK of BP1002 using elimination rate constant

    Time frame: 30 days

  8. Determine half-life plasma pharmacokinetics (PK) of BP1002

    Evaluate in vivo PK of BP1002 half-life (t1/2)

    Time frame: 30 days

  9. Identify conduction and rhythm changes (treatment emergent QTc elevations or other treatment emergent changes in ECG intervals) of escalating doses of BP1002

    Collection of 12-lead ECGs at defined intervals to identify conduction and rhythm changes (treatment emergent QTc elevations or other treatment emergent changes in ECG intervals)

    Time frame: 30 days

  10. Determine pharmacodynamics (PD) of BP1002

    Flow cytometry will be performed using peripheral blood to evaluate Bcl-2 target inhibition by BP1002 on pre and post treatment samples

    Time frame: 30 days

  11. Determine anti-drug antibody (ADA) levels of BP1002

    Evaluate ADA via peripheral blood

    Time frame: 30 days

Secondary outcomes

  1. Determine evidence of response by bone marrow aspirate

    Assess complete remission (CR), CR with incomplete hematologic recovery (CRi), and CR with partial hematologic recovery (CRh) per Döhner 2017

    Time frame: 180 days

  2. Determine evidence of response by complete blood counts using peripheral blood

    Assess complete remission (CR), CR with incomplete hematologic recovery (CRi), and CR with partial hematologic recovery (CRh) per Döhner 2017

    Time frame: 180 days

  3. Assessment of morphologic leukemia free state (MLFS) and partial remissions by bone marrow aspirate and complete blood counts

    To assess percentage of participants with MLFS and partial remissions per Döhner 2017

    Time frame: 180 days

  4. Assessment of morphologic leukemia free state (MLFS) and partial remissions by bone marrow aspirate

    To assess percentage of participants with MLFS and partial remissions per Döhner 2017

    Time frame: 180 days

  5. Assessment of blast count reductions by complete blood counts using peripheral blood

    To assess blast count reductions per Williams 2016

    Time frame: 180 days

  6. To determine progression-free survival (PFS), overall survival (OS), and duration of response

    To assess progression-free survival (PFS), overall survival (OS), and duration of response from date of study entry to study closure or death

    Time frame: 180 days

Other outcomes

  1. Exploratory objective to correlate treatment response with cytogenetic characteristics

    Flow cytometry assays to determine the effects of BP1002 on Bcl-2 protein expression

    Time frame: 30 days

  2. Exploratory objective to correlate treatment response with molecular characteristics

    Flow cytometry assays to determine the effects of BP1002 on Bcl-2 protein expression

    Time frame: 30 days

07

Study locations

4 of 4 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Mar 2027, 55 months after the start.

Of 182 industry-sponsored phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 62. This study's planned 55 months is above that.

Counting every sponsor, half of 489 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2021
First posted
Jan 13, 2022
StartActual
Aug 16, 2022
Primary completionEst.
Mar 2027
CompletionEst.
Sep 2027
Last update
Mar 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05190471
Lead sponsor
Bio-Path Holdings, Inc.
Responsible party
Sponsor
First posted
Jan 13, 2022
Start date
Aug 16, 2022
Primary completion
Mar 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Mar 10, 2025

Study contacts

Michael Hickey
Contact
mhickey@biopathholdings.com
832-742-1361
Gail J Roboz, MD
principal investigator · Weill Cornell Medical College - New York-Presbyterian Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Oblimersen · Decitabine

Start the discussion